Protalix Operating Income from 2010 to 2026

PLX Stock

USD 2.08 0.01 0.48%

Protalix Biotherapeutics Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2026. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Protalix Biotherapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

1996-09-30

Previous Quarter

1.2 M

Current Value

2.1 M

Quarterly Volatility

4.7 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.2 M, Selling General Administrative of 49.3 M or Other Operating Expenses of 32.3 M, as well as many indicators such as Price To Sales Ratio of 2.79, Dividend Yield of 0.0 or PTB Ratio of 3.45. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.

Build AI portfolio with Protalix Stock

Check out the analysis of Protalix Biotherapeutics Correlation against competitors.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Latest Protalix Biotherapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Protalix Biotherapeutics over the last few years. Operating Income is the amount of profit realized from Protalix Biotherapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Protalix Biotherapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Protalix Biotherapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protalix Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Protalix Operating Income Regression Statistics

	Arithmetic Mean	(13,821,129)
	Geometric Mean	9,365,603
	Coefficient Of Variation	(112.55)
	Mean Deviation	13,265,526
	Median	(13,014,000)
	Standard Deviation	15,555,508
	Sample Variance	242T
	Range	47M
	R-Value	0.61
	Mean Square Error	163.2T
	R-Squared	0.37
	Significance	0.01
	Slope	1,867,949
	Total Sum of Squares	3871.6T

Protalix Operating Income History

	2026	3.7 M
	2025	3.5 M
	2024	3.9 M
	2023	10.5 M
	2022	-13 M
	2021	-20.5 M
	2020	2.7 M

Other Fundumenentals of Protalix Biotherapeutics

Non Operating Income Net Other

Protalix Biotherapeutics Operating Income component correlations

	Total Assets	Net Debt	Net Receivables	Total Liab	Total Current Assets	Total Stockholder Equity	Retained Earnings	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt	Capital Surpluse	Short Long Term Debt	Long Term Debt Total	Net Invested Capital	Cash And Equivalents	Net Working Capital	Capital Stock
Total Assets		-0.22	-0.02	0.45	0.99	0.11	-0.27	0.46	0.56	0.08	0.08	0.5	-0.12	0.32	0.5	0.15	0.12	-0.07	0.23	0.14	0.18	0.17
Net Debt	-0.22		0.12	0.27	-0.17	-0.48	-0.32	0.23	-0.29	-0.05	0.03	-0.55	0.17	-0.52	0.19	0.15	-0.29	-0.05	-0.36	-0.39	-0.76	-0.44
Net Receivables	-0.02	0.12		0.04	-0.1	-0.07	-0.61	-0.27	-0.02	0.53	0.23	0.19	0.11	-0.2	0.07	0.45	-0.55	-0.26	-0.07	-0.52	-0.27	-0.45
Total Liab	0.45	0.27	0.04		0.44	-0.79	-0.07	0.42	0.41	0.31	-0.36	0.25	0.41	-0.52	0.59	-0.41	0.09	0.53	-0.58	0.33	-0.17	0.23
Total Current Assets	0.99	-0.17	-0.1	0.44		0.13	-0.24	0.46	0.57	-0.04	0.08	0.38	-0.13	0.34	0.56	0.14	0.11	-0.05	0.23	0.17	0.21	0.2
Total Stockholder Equity	0.11	-0.48	-0.07	-0.79	0.13		-0.11	-0.17	-0.1	-0.32	0.49	0.03	-0.56	0.8	-0.3	0.5	-0.01	-0.69	0.86	-0.3	0.35	-0.19
Retained Earnings	-0.27	-0.32	-0.61	-0.07	-0.24	-0.11		0.08	-0.05	-0.27	-0.58	0.02	-0.18	0.03	-0.15	-0.83	0.74	0.63	-0.2	0.76	0.44	0.72
Short Term Debt	0.46	0.23	-0.27	0.42	0.46	-0.17	0.08		0.08	0.08	-0.05	0.27	-0.17	0.0	0.0	-0.2	0.41	0.0	0.06	0.13	-0.28	0.09
Common Stock	0.56	-0.29	-0.02	0.41	0.57	-0.1	-0.05	0.08		0.16	-0.34	0.27	0.16	0.07	0.37	-0.11	-0.09	0.28	-0.03	0.42	0.49	0.61
Accounts Payable	0.08	-0.05	0.53	0.31	-0.04	-0.32	-0.27	0.08	0.16		0.06	0.59	0.36	-0.14	-0.19	0.01	-0.12	0.05	-0.16	-0.03	-0.23	-0.12
Short Term Investments	0.08	0.03	0.23	-0.36	0.08	0.49	-0.58	-0.05	-0.34	0.06		-0.02	-0.26	0.37	-0.26	0.7	-0.32	-0.75	0.55	-0.51	-0.23	-0.67
Property Plant Equipment	0.5	-0.55	0.19	0.25	0.38	0.03	0.02	0.27	0.27	0.59	-0.02		-0.13	0.28	-0.16	-0.17	0.44	0.03	0.2	0.25	0.17	0.23
Current Deferred Revenue	-0.12	0.17	0.11	0.41	-0.13	-0.56	-0.18	-0.17	0.16	0.36	-0.26	-0.13		-0.46	0.2	-0.06	-0.47	0.37	-0.5	0.07	-0.17	-0.01
Net Tangible Assets	0.32	-0.52	-0.2	-0.52	0.34	0.8	0.03	0.0	0.07	-0.14	0.37	0.28	-0.46		-0.27	0.23	0.24	-0.36	0.63	0.03	0.34	0.03
Long Term Debt	0.5	0.19	0.07	0.59	0.56	-0.3	-0.15	0.0	0.37	-0.19	-0.26	-0.16	0.2	-0.27		-0.07	-0.14	0.3	-0.28	0.15	0.18	0.16
Capital Surpluse	0.15	0.15	0.45	-0.41	0.14	0.5	-0.83	-0.2	-0.11	0.01	0.7	-0.17	-0.06	0.23	-0.07		-0.7	-0.82	0.49	-0.82	-0.27	-0.71
Short Long Term Debt	0.12	-0.29	-0.55	0.09	0.11	-0.01	0.74	0.41	-0.09	-0.12	-0.32	0.44	-0.47	0.24	-0.14	-0.7		0.31	0.08	0.6	0.22	0.52
Long Term Debt Total	-0.07	-0.05	-0.26	0.53	-0.05	-0.69	0.63	0.0	0.28	0.05	-0.75	0.03	0.37	-0.36	0.3	-0.82	0.31		-0.78	0.79	0.28	0.69
Net Invested Capital	0.23	-0.36	-0.07	-0.58	0.23	0.86	-0.2	0.06	-0.03	-0.16	0.55	0.2	-0.5	0.63	-0.28	0.49	0.08	-0.78		-0.29	0.25	-0.19
Cash And Equivalents	0.14	-0.39	-0.52	0.33	0.17	-0.3	0.76	0.13	0.42	-0.03	-0.51	0.25	0.07	0.03	0.15	-0.82	0.6	0.79	-0.29		0.6	0.9
Net Working Capital	0.18	-0.76	-0.27	-0.17	0.21	0.35	0.44	-0.28	0.49	-0.23	-0.23	0.17	-0.17	0.34	0.18	-0.27	0.22	0.28	0.25	0.6		0.67
Capital Stock	0.17	-0.44	-0.45	0.23	0.2	-0.19	0.72	0.09	0.61	-0.12	-0.67	0.23	-0.01	0.03	0.16	-0.71	0.52	0.69	-0.19	0.9	0.67

Click cells to compare fundamentals

About Protalix Biotherapeutics Financial Statements

Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	3.5 M	3.7 M
Non Operating Income Net Other	-6.8 M	-7.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
V	Visa Class A
CRM	Salesforce

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Protalix Operating Income from 2010 to 2026

Latest Protalix Biotherapeutics' Operating Income Growth Pattern

Protalix Operating Income Regression Statistics

Protalix Operating Income History

Other Fundumenentals of Protalix Biotherapeutics

Protalix Biotherapeutics Operating Income component correlations

About Protalix Biotherapeutics Financial Statements

Also Currently Popular

Additional Tools for Protalix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY